Skip to main content
. 2018 Feb 6;41(5):2461–2472. doi: 10.3892/ijmm.2018.3462

Figure 6.

Figure 6

NVP-BEZ235 inhibits the hypoxia-induced proliferation, migration and differentiation of rat PAFs in a dose- and time-dependent manner. (A) The proliferation results of PAFs treated with increasing concentrations of NVP-BEZ235 as measured by a CCK-8 assay (n=8). (B) The proliferation results of PAFs treated with 10 nM NVP-BEZ235 for increasing periods of time as measured by a CCK-8 assay (n=8). The cell migration results of PAFs treated with (C) increasing concentrations of NVP-BEZ235 and (D) 10 nM NVP-BEZ235 for increasing time periods as measured by a Transwell assay (n=8). (E) Western blot analysis of the expression of α-SMA and β-actin in PAFs treated with increasing concentrations of NVP-BEZ235 for 24 h. (F) Quantitative analysis of the α-SMA expression observed in the western blot analyses (n=3). (G) Western blot analysis of the expression of α-SMA and GAPDH in PAFs treated with 10 nM NVP-BEZ235 for increasing time periods. (H) Quantitative analysis of the α-SMA expression observed in the western blot analyses (n=3). PAFs, pulmonary arterial fibroblasts; CCK-8, cell counting kit-8; α-SMA, α-smooth muscle actin. *P<0.05, **P<0.01 and ***P<0.001.